Clinical trials · Tennessee
Solid Tumor clinical trials in Tennessee
We’re tracking 222 recruiting solid tumor studies with a site in Tennessee — including Early Phase 1, Phase 1 and Phase 1/Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07416123RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
Germantown, TennesseeAges 18 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Nashville, TennesseeAges 18 years+ - NCT06526819RecruitingPhase 1/Phase 2
New drug SMP-3124LP for advanced solid tumors
This trial tests a new drug called SMP-3124LP for people with advanced solid tumors that no longer respond to standard treatments. It is given in two phases: first to find the best dose (dose escalation) and then to see how well it works in specific cancer types (dose expansion).
Nashville, TennesseeAges 18 years+ - NCT06462794RecruitingPhase 1
Study of CX-801 for advanced solid tumors
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT05645523RecruitingEarly Phase 1
ICG dye mapping to find lymph nodes in some childhood tumors
This early study tests using a special dye (indocyanine green, or ICG) to help surgeons find the correct “sentinel” lymph nodes during surgery in children with certain suspected tumors. If successful, it may improve how doctors remove and check lymph nodes while reducing the chance of missing important areas.
Memphis, TennesseeAges Up to 20 years - NCT06885281RecruitingPhase 1/Phase 2
Study of ZL-1310 for neuroendocrine carcinoma
This trial is testing an experimental drug called ZL-1310 for people with neuroendocrine carcinoma (a rare, fast-growing cancer) that has spread or can't be removed. It aims to see if the drug is safe and works against the cancer.
Nashville, TennesseeAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Nashville, TennesseeAges 18 years+ - NCT06265688RecruitingPhase 1
First study of CX-2051 for advanced solid tumors
This study is testing a new drug called CX-2051 for people with advanced solid tumors that have not responded to standard treatments. The drug is a type of targeted therapy that delivers chemotherapy directly to cancer cells, and the goal is to see if it is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06874335RecruitingPhase 1
A study of BHV-1530 for advanced solid tumors
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06554795RecruitingPhase 1/Phase 2
Testing DB-1419 for advanced solid tumors
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT05907980RecruitingPhase 1
ROSE12 alone and with other drugs for advanced solid tumors
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06603844RecruitingPhase 1/Phase 2
Study of CRB-601-01 for advanced solid tumors
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
Nashville, TennesseeAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Nashville, TennesseeAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Memphis, TennesseeAges Up to 25 years - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Nashville, TennesseeAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Nashville, TennesseeAges 12 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Nashville, TennesseeAges 18 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Memphis, TennesseeAges 1–30
Solid Tumor trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting solid tumor studies listed above.
- SCRI Oncology Partners · 7 studies
- Sarah Cannon Research Institute · 4 studies
- Vanderbilt University Medical Center · 4 studies
- St. Jude Children's Research Hospital · 3 studies
- Tennessee Oncology · 3 studies
- SCRI · 2 studies
- Avenzo Therapeutics Recruiting Site
- Investigative Site #102
What taking part in a solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Solid Tumor trials in other states
Common questions
- Are there solid tumor clinical trials in Tennessee?
- Yes. We're currently tracking 222 recruiting solid tumor studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.